Therapeutic interventions targeting the JAK-STAT pathway, particularly JAK inhibitors, have been therapeutically validated in rheumatoid arthritis, ulcerative colitis, ankylosing spondylitis, atopic dermatitis, myelofibrosis, and other diseases.[18] The specific targeted therapies known as JAK2 inhibitors, such as ruxolitinib and phetrotinib, can be employed in case of no response to other treatment or not well-tolerated without considering the mutation of JAK2/V617F. The gene discussed is SOAT1; the disease is atopic eczema.